AVEO Oncology Announces Presentations at the 2019 ASCO Annual Meeting
May 15 2019 - 5:00PM
Business Wire
AVEO Oncology (NASDAQ: AVEO) today announced two poster
presentations at the upcoming American Society of Clinical Oncology
(ASCO) Annual Meeting being held May 31-June 4, 2019 in Chicago,
Illinois.
Presentation Details
Title: Efficacy and safety of tivozanib in recurrent,
platinum-resistant ovarian, fallopian tube or primary peritoneal
cancerFirst Author: Wendy M. Swetzig, PhD, Northwestern
University Feinberg School of MedicineAbstract Number:
5538Poster Session: Gynecologic CancerPoster Board:
361Date and Time: Saturday, June 1, 2019, 1:15-4:15 PM
CTLocation: Hall A
Title: TIVO-3: Subgroup analysis of progression-free
survival of tivozanib compared to sorafenib in subjects with
refractory advanced renal cell carcinoma (RCC)First Author:
Camillo Porta, MD, Associate Professor, Department of Internal
Medicine, University of Pavia and Division of Translational
Oncology, IRCCS Maugeri, ItalyAbstract Number: 4572Poster
Session: Genitourinary (Nonprostate) CancerPoster Board:
398Date and Time: Monday, June 3, 2019, 1:15-4:15 PM
CTLocation: Hall A
About Tivozanib (FOTIVDA®)
Tivozanib (FOTIVDA®) is an oral, once-daily, vascular
endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI)
discovered by Kyowa Hakko Kirin and approved for the
treatment of adult patients with advanced renal cell carcinoma
(RCC) in the European Union
plus Norway and Iceland. It is a potent, selective
and long half-life inhibitor of all three VEGF receptors and is
designed to optimize VEGF blockade while minimizing off-target
toxicities, potentially resulting in improved efficacy and minimal
dose modifications.1,2 Tivozanib has been shown to
significantly reduce regulatory T-cell production in preclinical
models3 and has demonstrated synergy in combination with
nivolumab (anti PD-1) in a Phase 1/2 study in RCC. Tivozanib has
been investigated in several tumor types, including renal cell,
hepatocellular, colorectal and breast cancers. In addition, a new
formulation of tivozanib is in pre-clinical development for the
treatment of age-related macular degeneration.
About AVEO
AVEO Pharmaceuticals, Inc. (the “Company” or “AVEO”) is a
biopharmaceutical company seeking to advance targeted medicines for
oncology and other unmet medical needs. The Company is working to
develop and commercialize its lead candidate tivozanib in North
America as a treatment for RCC. The Company has sublicensed
tivozanib (FOTIVDA®) for oncological indications in Europe and
other territories outside of North America. Tivozanib is approved
in the European Union, as well as Norway and Iceland, for the
first-line treatment of adult patients with RCC and for adult
patients who are vascular endothelial growth factor receptor and
mTOR pathway inhibitor-naïve following disease progression after
one prior treatment with cytokine therapy for RCC. The Company also
has clinical collaborations to study tivozanib in combination with
immune checkpoint inhibitors in RCC and in hepatocellular
carcinoma. In addition, a new formulation of tivozanib is in
pre-clinical development for the treatment of age-related macular
degeneration. As part of the Company’s strategy, the Company has
also entered into partnerships to help fund the development and
commercialization of its other product candidates. Ficlatuzumab, a
hepatocyte growth factor inhibitory antibody, is currently being
tested in several investigator sponsored studies jointly funded by
the Company and one of its development partners for the potential
treatment of head and neck squamous cell carcinoma, acute myeloid
leukemia, and pancreatic ductal adenocarcinoma. The Company’s
partner for AV-203, an anti-ErbB3 monoclonal antibody, is planning
to initiate clinical studies in China in 2019 in esophageal
squamous cell carcinoma and has committed to funding the
development of AV-203 through proof-of-concept. The Company has
recently regained the rights to AV-380, a humanized IgG1 inhibitory
monoclonal antibody targeting growth differentiation factor 15, a
divergent member of the TGF-ß family, for the potential treatment
of cancer cachexia, and is working to initiate preclinical
toxicology studies in 2019 to support the potential filing of an
investigational new drug application with the FDA. The Company is
evaluating options for the development of AV-353, a preclinical
asset which targets the Notch 3 pathway.
For more information, please visit the Company’s website at
www.aveooncology.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO
within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve substantial risks and uncertainties. All
statements, other than statements of historical fact, contained in
this press release are forward-looking statements. Actual results
or events could differ materially due to a number of important
factors, including risks discussed in the section titled “Risk
Factors” in AVEO’s most recent Annual Report on Form 10-K, its
quarterly reports on Form 10-Q and its other filings with the SEC.
The forward-looking statements in this press release represent
AVEO’s views as of the date of this press release. AVEO anticipates
that subsequent events and developments may cause its views to
change. While AVEO may elect to update these forward-looking
statements at some point in the future, it specifically disclaims
any obligation to do so. You should, therefore, not rely on these
forward-looking statements as representing AVEO’s views as of any
date other than the date of this press release.
References
1. Fotivda (Tivozanib) SmPC August 20172. Motzer RJ, Nosov D,
Eisen T, et al. J Clin Oncol 2013; 31(30): 3791-9.3. Pawlowski N et
al. AACR 2013. Poster 3971.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190515005917/en/
AVEO:David Pitts, Argot Partners(212) 600-1902
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From May 2024 to Jun 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Jun 2023 to Jun 2024